書誌情報
P14-5. Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed Refractory Multiple Myeloma : Safety, Efficacy, and Immune Profile
David S.Siegel1, Gary J Schiller2, Christy Samaras3, Jesus Berdeja4, Siddhartha Ganguly5, Jeffrey Matous6, Kevin Song7, Christopher S.Seet8, Giampaolo Talamo9, Mirelis Acosta-Rivera10, Michael Bar11, Donald Quick12, Bertrand Anz13, Gustavo Fonseca14, Donna Reece15, Amit Agarwal16, Weiyuan Chung16, William Pierceall16, Faiza Zafar16, Nizar J. Bahlis17
1John Theurer Cancer Center, Hackensack University Medical Center, 2David Geffen School of Medicine at University of California, 3Cleveland Clinic, 4Sarah Cannon Research Institute, 5The University of Kansas Cancer Center, 6Colorado Blood Cancer Institute, 7Vancouver General Hospital, 8University of California, Los Angeles Medical Center, 9Penn State Hershey Cancer Institute, 10Fundacion de Investigacion, 11Stamford Hospital, 12Joe Arrington Cancer Research and Treatment Center, 13Tennessee Oncology, 14Florida Cancer Specialists, 15Princess Margaret Cancer Centre, 16Celgene Corporation, 17University of Calgary
International Journal of Myeloma 9(1): 151-151, 2019.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
